Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

Annals of Oncology

Volumn 25, Issue 9, 2014, Pages 1735-1742

  Mittendorf, E A ^a   Clifton, G T ^b   Holmes, J P ^c   Schneble, E ^d   van Echo, D ^e   Ponniah, S ^f   Peoples, G E ^d,f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BLANCHFIELD ARMY COMMUNITY HOSPITAL   (United States)

^c Redwood Regional Medical Group   (United States)

^d BROOKE ARMY MEDICAL CENTER   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Breast cancer; Immunotherapy; Nelipepimut S; Vaccine

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; HLA A3 ANTIGEN; IMMUNOLOGICAL ADJUVANT; PEPTIDE FRAGMENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; ESTROGEN RECEPTOR; NELIPEPIMUT S; PROGESTERONE RECEPTOR; SODIUM CHLORIDE; TRASTUZUMAB;

ADULT; AGED; BREAST; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREVENTION AND CONTROL; PROCEDURES; SECONDARY IMMUNIZATION; TUMOR RECURRENCE; VACCINATION; ADJUVANT THERAPY; ARTICLE; BONE PAIN; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; HIGH RISK PATIENT; HORMONAL THERAPY; IMMUNOHISTOCHEMISTRY; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INOCULATION; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OPTIMAL DRUG DOSE; PARTIAL MASTECTOMY; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PRURITUS; TREATMENT OUTCOME; URTICARIA;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; BREAST; BREAST NEOPLASMS; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A2 ANTIGEN; HLA-A3 ANTIGEN; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOTHERAPY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; VACCINATION;

EID: 84906847366     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu211     Document Type: Article

References (19)

1. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 2008; 57: 1511-1521.
2. Brossart P, Wirths S, Stuhler G et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96: 3102-3108.
3. Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20: 2624-2632.
4. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptidespecific immunity. Clin Cancer Res 2002; 8: 1014-1018.
5. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 1998; 58: 4902-4908.
6. Peoples GE, Holmes JP, Hueman MT et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients. Clin Cancer Res 2008; 14: 797-803.
7. Holmes JP, Clifton GT, Patil R et al. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine. Cancer 2011; 117: 463-471.
8. Mittendorf EA, Clifton GT, Holmes JP et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients. Cancer 2012; 118: 2594-2602.
9. Peoples GE, Gurney JM, Hueman MT et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005; 23: 7536-7545.
10. Benavides LC, Gates JD, Carmichael MG et al. The impact of HER2/neu expression level on response to the E75 vaccine. Clin Cancer Res 2009; 15: 2895-2904.
11. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
12. Morton DL, Ollila DW, Hsueh EC et al. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin 1999; 49: 101-116, 165.
13. Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364: 2119-2127.
14. Overwijk WW, Theoret MR, Restifo NP. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am 2000; 6(Suppl 1): S76-S80.
15. Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-3373.
16. Lau LL, Jamieson BD, Somasundaram T, Ahmed R. Cytotoxic T-cell memory without antigen. Nature 1994; 369: 648-652.
17. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity 2010; 33: 451-463.
18. Ricupito A, Grioni M, Calcinotto A et al. Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. Cancer Res 2013; 73: 3545-3554.
19. Efficacy and Safety Study of NeuVax(TM) (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence (PRESENT); http://clinicaltrials.gov/show/NCT01479244 (3 February 2014, date last accessed).